p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
Impact in
- Oncology 237
Classified as
- Journal
- PubMed
In The Last Decade
doi.org/w70016205 →Countries where authors are citing p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
This map shows the geographic impact of p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. more than expected).
Fields of papers citing p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
This network shows the impact of p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents..
About p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
This paper, published in 1994, received 358 indexed citations . Written by Saijun Fan, Wafik S. El‐Deiry, I Bae, Kishor Bhatia, Albert J. Fornace, Ian Magrath, Kurt W. Kohn and P M O'Connor covering the research area of Oncology and Molecular Biology. It is primarily cited by scholars working on Oncology (237 citations), Molecular Biology (206 citations), Biotechnology (72 citations), Cancer Research (58 citations) and Pathology and Forensic Medicine (32 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w70016205.